{"entity":{"id":"nct07162181","kind":"trial","name":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers","aka":[],"tldr":"A phase 2 trial of Pirtobrutinib in non-hodgkin lymphoma, run by Eli Lilly and Company, active and no longer recruiting.","summary":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers is a phase 2 interventional study registered as NCT07162181 by Eli Lilly and Company, with 13 participants planned, started 2025-08-07 and due to reach its primary completion in 2030-05. Interventions recorded: Pirtobrutinib. Conditions listed: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07162181","url":"https://clinicaltrials.gov/study/NCT07162181"}],"tags":["ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pirtobrutinib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07162181","phase":"2","setting":"Long-Term Safety of Pirtobrutinib in Participants From Study J2N-MC-JZNJ With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma","sponsor":"Eli Lilly and Company","enrolled":13,"outcomes":[]},"route":"/trials/nct07162181/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}